25 Sep 2025 | 3 Mins Read
Glenmark Pharma soars on $1.1 billion oncology deal
Flipitmoney
Glenmark Pharmaceuticals signed an exclusive licensing and collaboration pact with Hengrui Pharma for Trastuzumab Rezetecan, a HER2-targeting ADC, worth up to $1.093 billion including regulatory, commercial milestone payouts and royalties. Glenmark will make a $18 million upfront payment and has exclusive global rights, excluding certain countries.